Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio
Type of Publication
Journal Article
Year of Publication
2018
Journal
Cardiovasc Diabetol
DOI
10.1186/s12933-018-0682-3
Language
Eng
ISSN Number
1475-2840
Volume
17
Issue
1
Number of Pages
39
Links to full text